Aims: Little evidence exists supporting the efficacy of regular alcohol urine screening (RAUS) in the management of alcohol dependence, despite recent improvements in urine biomarkers. In this study, we aimed at investigating 1 year, differential clinical correlates between a positive and a negative baseline urine ethyl glucuronide (EtG) screening. Methods: Alcohol-dependent outpatients participating in a previous cross-sectional study where EtG and ethanol diagnostic performances were compared in a double blind design were included. After 1 year, the presence of relapse, the number of hospitalizations and whether patients had abandoned treatment or not were assessed from electronic medical records. A survival analysis was conducted to compare time to relapse between EtG negative and positive subjects. Regression models were performed to compare the mean number of days hospitalized between groups, the risk of being lost to follow-up and treatment expenses. Results: Of note, 152 patients (mean age 52, 67% males) were included. The mean time to relapse was of 163 days in EtG positive subjects, compared to 329 days in those with a negative result. In the Cox-regression model, only EtG positivity yielded significant results, with a hazard ratio of 5:3 (95% CI: 3.1-9.1). EtG positive was also the only significant predictor of a greater number of hospitalization days and treatment expenses. Younger age was the only variable predicting a greater risk of treatment abandonment. Conclusion: RAUS with sensible biomarkers could improve clinicians' ability to assess patients' relapse risk. Further prospective studies will have to determine if this can be translated into a better prevention capacity. Short summary: Positive urine screenings, when conducted with highly sensible alcohol biomarkers, significantly indicate a greater risk of relapse in alcohol-dependent patients and have the capacity to predict a greater risk of hospitalization and greater treatment expenses.
INTRODUCTION
Alcohol is one of the leading drivers of harm worldwide (Whiteford et al., 2013; Christopher and Murray, 2016) . Its consequences affect both individuals and societies as a whole (Barrio et al.; in press ). Individuals causing the greatest part of this harm are those who are dependent on it (Mohapatra et al., 2010) . Therefore, alcohol dependence should be considered as a top priority from a public health perspective (WHO, 2014) .
The proper management of alcohol dependence requires the use of several strategies, from psychosocial to pharmacological ones. One frequently used element, especially in abstinence oriented settings, is regular alcohol urine screening (SAMHSA 2012; American Society of Addiciton Medicine, 2014) . Traditional markers used for this purpose remain suboptimal with regard to sensitivity and specificity, especially when it comes to detecting recent drinking. Ethanol remains detectable only for~8-12 h post ingestion, whereas other traditional markers such as gamma glutamyltransferase, mean corpuscular volume or carbohydrate deficient trasnferrin need persistent consumption of higher amounts of alcohol (>2 weeks, >1000 g of ethanol in 2 weeks) to become elevated.
Fortunately, in recent years there has been a noticeable improvement in the sensibility and specificity of biomarkers of alcohol consumption, with the appearance of more sensible and specific markers, such as ethyl glucuronide (EtG), ethyl sulfate or phosphatidylethanol (Wurst et al. 2015) . They all expand the time window for the detection of recent alcohol consumption in urine samples. This might offer relevant improvements in clinical practice, in as much as covert drinking might be more frequently detected and so earlier addressed, Up to date, EtG has the advantage of an existing commercially available enzyme immunoassay (EIA) method based on a new monoclonal antibody (Diagnostic Reagents Incorporated-EtG EIA, Thermo Fisher Scientific Diagnostics, Hemel Hempstead, UK), that allows for a more cost-effective detection of EtG in urine samples. However, despite the wide use of frequent urine screening and the recent improvements in its biomarkers, little evidence exists supporting its clinical efficacy in alcohol dependence (Dupouy et al. 2014) .
In a recent cross-sectional study , we found that under routine clinical conditions, EtG performed largely better than ethanol, self-report and clinical judgment in the detection of recent drinking. In fact, a solid body of evidence demonstrates that EtG performs largely better than self-reports and ethanol in the detection of recent drinking (Wurst et al., 2004; Junghanns et al., 2009; Dahl et al., 2011; Jatlow et al., 2014; Leickly et al., 2015) . Given that both patients and clinicians were unaware of EtG results and that patients were followed-up as part of their usual treatment during the following year, and subsequent urinary assessments were done with ethanol, we had the opportunity to assess the differential, 1-year correlates of a baseline EtG positive urine screening. We believe that this is a relevant issue, since it allows for a more detailed and precise delineation of what is really a positive urine screening with a highly sensible biomarker telling us, when we face an alcohol addicted patient with regard to risk of relapse, risk of hospitalization and what its economic implications are, something that has not been previously studied. It must be noted that subsequent urinary assessments were performed with ethanol instead of EtG because ethanol was the routine marker used in our laboratory, and during the study period, we had not the chance to routinely utilize EtG as a marker of alcohol consumption.
While there is a solid body of evidence assessing the predictive capacity of other variables such as illness severity (Langenbucher et al., 1996) , craving (Bottlender and Koyka, 2004) , DSM-IV criteria (Fazzino et al., 2014) or other psychological constructs such as persistence and self-efficacy (Cannon et al., 1997) when trying to determine the risk of relapse, there is no such literature related to the predictive capacity of urine screenings. And the same happens when analyzing the risk of hospitalization (Lawder et al., 2011; Hong et al., 2014; Chang et al., 2016) . The objective of the present study was to analyze 1-year correlates of a EtG positive urine screening, with special attention to relapse and the need of hospitalization. We also tried to estimate costs related to addiction treatment for both EtG and EtG negative subjects in the following year.
MATERIALS AND METHODS

Subjects
Participants were previously recruited in a study comparing the performance of urinary EtG in routine clinical conditions . Subjects were adult alcohol-dependent patients receiving treatment in an outpatient department from a big tertiary urban hospital in Barcelona. In the initial study, in a cross-sectional design, patients were tested for both ethanol and EtG in their urine, incorporating also patients' self-reports and the judgment of the attending nurse. Patients were unaware of EtG testing, and the results obtained were not available to their treating clinicians. For the present study, patients were divided into two cohorts, those who screened positive for EtG and those who screened negative for EtG. Patients that were actively and overtly drinking at baseline were excluded from this study, since they could not be incorporated into the main survival analysis. Ethics approval was granted from the Clinic Hospital of Barcelona IRB (decision number HCB/2015/ 0984).
Measurements
Basic sociodemographic and clinical data, as well as the baseline value of urinary EtG, were extracted from the previous study. One year after the study was completed, electronic medical records from participants were reviewed for data collection and analysis. The number of total or partial hospitalizations (day hospital) was recorded.
The main outcome of the study was defined as relapse, which was operationalized as meeting any of the following criteria:
(1) Need for total or partial (day hospital) hospitalization, or emergency department attendance, due to alcohol consumption. (2) Positivity of a urine screening (performed with ethanol). (3) Clinical detection, according to patient's medical record, of any alcohol consumption. This could be in the form of patient selfreport, significant others report or clinician report.
Time until relapse was also recorded. Other collected variables included the number of visits with an addiction professional that patients attended during the following year, the number of urine screenings performed and whether patients were lost to follow-up or not during this time. For economical evaluations, price per day of total or partial hospitalization and price per visit were obtained from the corresponding local agency.
Statistical analysis
To compare the differential rate of relapse between EtG positive and EtG negative subjects, a survival analysis was performed. The endpoint was defined as relapse, according to the first occurring criteria of the operationalization described above. Kaplan-Meier survival curves were plotted and compared with the log-rank test. A Cox-regression model was further conducted, including age, sex, addictive comorbidities and length of urine testing in order to adjust the contribution of an EtG positive urine screening at baseline as an indicator of relapse risk during the following year.
To compare hospitalizations between EtG positive and negative groups, a multivariate regression analysis was conducted with the mean number of days of hospitalization as the dependent variable. For this purpose, days of complete hospitalization and days of partial hospitalization (day hospital) were added together. Independent variables included EtG status at baseline, sex, age, addictive comorbidities and length of urine testing.
For economical evaluations, a price per day of total and partial hospitalization was gathered from the pertinent local health agency. A price was also fixed for every outpatient visit that patients completed. A mean price for each group (EtG positive vs EtG negative) was calculated. Also, a multivariate regression analysis was conducted with mean price as a dependent variable and EtG status at baseline, sex, age, addictive comorbidities and length of urine testing as independent predictors. Finally, the rate of patients lost during the next year was compared between EtG groups with binary logistic regression incorporating age, sex, addictive comorbidities and length of urine testing as independent variables.
In order to test whether other factors could replicate the prediction capacity of EtG, all models were performed again substituting EtG results by clinician judgment. Given the outlying few positive self-reports we had in the initial study, the use of this variable for another set of analysis was deemed inappropriate.
Data were analyzed using SPSS 21.0 (SPSS Inc., Chicago, Illinois). Ethanol measurement in urine was performed with molecular absorption spectroscopy.
RESULTS
At baseline, data were extracted from 185 patients, of which 33 were excluded from analysis since they were considered to be actively and overtly drinking. This could be because they had a positive ethanol result at baseline, because their self-report was positive or because the treating clinician had clearly identified the patient was actively drinking in that period of time. Since the main objective of the present paper was the survival analysis, they were excluded because they were considered to have already reached the endpoint before study initiation. Basic sociodemographic characteristics of both groups and clinical data gathered during the 1-year follow-up are compared in Table 1 .
The Kaplan-Meier curves comparing EtG positive and negative groups are displayed in Fig. 1 . The log-rank test revealed significant differences (chi = 58.382 df = 1; P < 0.001). The mean survival time of EtG positive subjects was 163 days, compared to 329 days in those with a negative result. In the Cox-regression model, only EtG positivity yielded significant results, with a hazard ratio of 5:3 (95% CI: 3.1-9.1).
In the comparison between hospitalizations, the multivariate regression analysis confirmed the significance of a positive EtG result at baseline as a predictor of increased number of days hospitalized, with b = 5.3 (95% CI: 2.1-8.4). The rest of the covariates were non-significant.
For economical evaluations, the following prices were established according to the local health agency recommendations-day of total hospitalization: 555 €; day of partial hospitalization (day hospital): 117€; outpatient visit with an addiction professional: 137 €. Calculations yielded a mean cost of 2.167 € for EtG positive patients, and 566 € for EtG negative patients. In the regression analysis, only EtG status was a significant predictor.
Finally, in the binary logistic regression conducted to investigate factors associated with the risk of being lost to follow-up during the year following EtG testing, EtG positivity was significant in the univariate analysis, but only age was a significant predictor in the final model, being older associated with a lesser risk of discontinuing treatment (OR = 0.94, 95% CI: 0.89-0.98).
When substituting EtG for clinician judgment, none of the models found a significant contribution of this variable. The survival curves according to the different clinician judgment (abstinent vs non-abstinent) are displayed in Fig. 2 (log-rank test not significant; chi = 3264 df = 1; P = 0.071).
DISCUSSION
In this study, we evaluated 1-year clinical correlates of a positive baseline EtG urine screening, as compared to a negative baseline result. Both patients and clinicians were unaware of baseline EtG results. Also, since we could not incorporate EtG testing as our routine biomarker due to budget and time constraints in the following year, the ongoing urine screenings were performed with ethanol. This in fact allowed the performance of the present study, where the implications of a single EtG testing could be evaluated. The data obtained during the follow-up suggest that patients testing positive in EtG will have a different clinical evolution in the following year, with a significant increase in relapses, hospitalizations and treatment expenses. Given that both patients and clinicians were unaware of EtG status at baseline, one pressing question emerges: could some of this differences have been avoided, was this information made available to them? Although such a question cannot be answered by this study, and needs for prospective, randomized investigations, we believe some clues can be drawn from our data.
Although the need for hospitalization for the whole sample was rather low, with only 10 patients (6.6% of the total sample) requiring it, the differences between groups were both significant and large, with only one patient in the EtG negative arm being hospitalized in the following year. Taking a stepped care approach, hospitalization could be considered as one of the final steps in dealing with a relapse, which might have been initiated much before in the form of lapses. This might be a crucial point in time where the use of sensible alcohol biomarkers such as EtG could help to identify the beginning of the relapse, and so to earlier address it, with the potential impact of avoiding the need for hospitalization and also of reducing treatment expenses.
Though at first glance suggesting that patients who test positive for EtG will relapse at a higher rate than those who do not could seem tautological, this fact deserves further elaboration. First, one should notice that relapse, though widely used as a concept, lacks firm and conclusive criteria (Maisto et al., 2016) , a fact that could explain that being EtG positive does not immediately imply a relapse. In fact, a minority of patients tested positive for EtG and were clinically deemed as non-relapsed during the following year. That being said, our data robustly show that an EtG positive dramatically increases the risk of having a clinical correlate in the following year, as shown by the hazard ratio obtained in the survival analysis. In other words, patients testing positive for EtG will, with very high probabilities, ultimately have clinical symptoms of relapse.
Therefore, an EtG positive screening could be considered as an early relapse sign. But also looked the other way around, it looks like having an EtG negative screening has a strong negative predictive value, that is, it should reassure clinicians regarding patients' favorable evolution, at least in alcohol-related outcomes.
Our results are in line with previous, similar studies. For example, Junghanns et al. (2009) , found out that positive EtG urine screening early after discharge significantly increased the rate of subsequent relapse in recently discharged alcohol-dependent patients. Similarly, Dahl et al. (2011) found EtG to be a useful and reliable ongoing monitoring tool in alcohol treatment studies, specially suggesting that an initial EtG negative sample is useful to confirm selfreports.
Treatment expenses were clearly different between groups, driven both by the different number of days of hospitalization in both cohorts as well as an increased number of visits in those EtG positive. In fact, it has already been shown that patients actively drinking incur in greater costs (Aldridge et al., 2016; Witkiewitz and Horn, 2016; Miquel et al., 2017) . Although it was not included in the cost analysis, it is worth mentioning that EtG positive patients had also much more frequent urine testing during the follow-up. All these data suggest that the implementation of EtG could also have an economic impact in the treatment of alcohol dependence.
Regarding the capacity of predicting the risk of being lost to follow-up, EtG showed significant results in the univariate analysis, which seemed to disappear once age was included in the multivariate model. In fact, previous literature already pointed out at older age as a predictor of treatment retention (Korte et al., 2011; . That being said, prior literature also consistently shows that patients actively using alcohol or drugs are at a greater risk of becoming non-treatment adherent (White et al., 2014; Campbell et al., 2016; . Also, previous studies with EtG (Junghanns et al., 2009 ) have found that testing EtG positive increases the risk of being lost to follow-up. Therefore, it would not be unwise to consider EtG as a potentially useful tool in predicting the risk of treatment abandonment. Taken together, we believe that the data gathered by this study has important implications for real practice. Although, as previously acknowledged, there exist many other variables with a demonstrated predictive capacity in alcohol-dependent patients regarding relapse risk and general outcome, it looks like the implementation of EtG in routine urine screening could improve clinicians capacity to detect early signs of relapse, and therefore it would also allow them to early address it, making the whole process more efficient. Also, it looks like both the positive and negative predictive values of EtG could allow for a better targeting of those patients that are in need of a more urgent, intense intervention. It means that an EtG positive patient should raise clinicians awareness and efforts immediately, while an EtG negative patient could reassure them of a favorable evolution, at least in the following months. Again, it is important to state that urine screening should not be a substitute of other assessments. However, in this study, we found it to be the most accurate, precise predictor, even when controlling for other variables such as age, sex, addictive comorbidities or length of urine testing, and also clearly better than clinical judgment.
Several limitations should be noticed when interpreting our study. First, data were gathered at the end of follow-up, which means that variables were collected retrospectively. Importantly, there exists the possibility that patients were hospitalized in other centers, which could have biased our data. However, it would be reasonable to consider that in both groups more hospitalizations would have been seen, and probably even more in the EtG positive patients. Therefore, this bias would result in an infraestimation of EtG prediction capacity, which as we showed, turn out to be already significant. Related to this, it is the fact that more EtG positive patients were lost to follow-up. While survival analysis specifically addresses this data, when analyzing days of hospitalization and relapse risk, they had to be considered as missing data. However, as previously mentioned, treatment abandonment has been associated with increased relapse risk; therefore, it is probable that this missing data turned out into an infraestimation of EtG prediction capacity regarding relapse risk and hospitalization risk. Also relevant to mention is the fact that relapse as an outcome was operationalized according to different criteria, a fact that could limit the validity of our results. Finally, it is important to note that psychiatric comorbidities, a frequent phenomenon in alcohol-dependent patients (Flensborg-Madsen et al., 2009; Fein, 2015) , were not systematically recorded in this study, and therefore, their contribution to the results obtained could not be evaluated.
All in all, we believe our study increases the available evidence supporting the usefulness and clinical impact of regular urine screening in alcohol treatments. Though no efficacy data could be directly inferred from our data, it looks like a wide implementation of sensible alcohol biomarkers could help to improve the prediction capacity of clinicians, especially in abstinence oriented settings. Further prospective studies will have to examine whether this increased prediction capacity can be translated into a greater treatment efficacy, probably due to a better prevention. 
